---
title: "The research enthusiasm for star companies is high, and leading enterprises frequently release positive signals"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/251259631.md"
description: "This week, 125 listed companies disclosed institutional research minutes, with nearly 40% of stocks achieving positive returns. Defu Technology and VGT rose more than 20%, while ChemPartner, DAYANG BIOTECH, ALD, and 7 other stocks rose more than 10%. The median price change of the surveyed stocks was -1.51%"
datetime: "2025-08-01T23:31:32.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/251259631.md)
  - [en](https://longbridge.com/en/news/251259631.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/251259631.md)
---

# The research enthusiasm for star companies is high, and leading enterprises frequently release positive signals

According to the Securities Times, Wind data shows that this week, a total of 125 listed companies disclosed institutional research minutes, with nearly 40% of the stocks researched by institutions achieving positive returns. Among them, Defu Technology and VGT saw increases of over 20%, while ChemPartner, DAYANG BIOTECH, ALD, and 7 other stocks rose by more than 10%. The median price change of the researched stocks was -1.51%

### Related Stocks

- [300149.CN](https://longbridge.com/en/quote/300149.CN.md)
- [003017.CN](https://longbridge.com/en/quote/003017.CN.md)
- [300696.CN](https://longbridge.com/en/quote/300696.CN.md)
- [301511.CN](https://longbridge.com/en/quote/301511.CN.md)
- [300476.CN](https://longbridge.com/en/quote/300476.CN.md)

## Related News & Research

- [The $1.2tn untapped pharma opportunity in tropical conservation](https://longbridge.com/en/news/294354505.md)
- [Cold-Chain Provider Shanghai Shengsheng Renews Hong Kong Listing Plan](https://longbridge.com/en/news/294397065.md)
- [China Resources Pharmaceutical Moves to Become Largest Shareholder in Lier Chemical](https://longbridge.com/en/news/294273054.md)
- [BUZZ-Sleep apnea pill developer Apnimed poised to jump in debut after upsized IPO](https://longbridge.com/en/news/294533308.md)
- [Sleep apnea pill developer Apnimed prices upsized IPO at $16, the high end of the range](https://longbridge.com/en/news/294514935.md)